Skip to main content

Table 2 Classification of patients receiving monotherapy or combination therapy

From: A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients

Therapy

Number of patients (%)

Monotherapy GnRH

724 (56.9)

Combination therapy

449 (35.3)

ā€ƒā€ƒā€ƒBicalutamide

183 (40.8)*

ā€ƒā€ƒā€ƒFlutamide

171 (38.1)*

ā€ƒā€ƒā€ƒZoledronic acid

59 (13.1)*

ā€ƒā€ƒā€ƒCyproterone

57 (12.7)*

ā€ƒā€ƒā€ƒOestramustine

12 (2.7)*

ā€ƒā€ƒā€ƒDocetaxel

6 (1.3)*

ā€ƒā€ƒā€ƒMissing data

10 (2.2)*

ā€ƒā€ƒā€ƒTotal

498 (**)

Missing data

100 (7.9)

Total

1273 (100.0)

  1. *Percentage refers to patients receiving a combination therapy (n = 449); **Total includes multiple naming for combination therapy: Single: 405; 2-fold: 40; 3-fold: 3; 4-fold: 1